304 related articles for article (PubMed ID: 3872261)
21. Anti-C1q column: ligand specific purification of immune complexes from human serum or plasma. Analysis of the interaction between C1q and immune complexes.
Kilgallon W; Amlot PL; Williams BD
Clin Exp Immunol; 1982 Jun; 48(3):705-14. PubMed ID: 6811171
[TBL] [Abstract][Full Text] [Related]
22. Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor.
Doekes G; Schouten J; Cats A; Daha MR
Immunology; 1985 Jul; 55(3):555-64. PubMed ID: 4018839
[TBL] [Abstract][Full Text] [Related]
23. C1 subcomponent complexes: basic and clinical aspects.
Laurell AB; Sjöholm AG
Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
[TBL] [Abstract][Full Text] [Related]
24. A study of in vivo immune complex formation and clearance in man.
Davies KA; Hird V; Stewart S; Sivolapenko GB; Jose P; Epenetos AA; Walport MJ
J Immunol; 1990 Jun; 144(12):4613-20. PubMed ID: 2141040
[TBL] [Abstract][Full Text] [Related]
25. Purification and characterization of the 1q subcomponent of canine complement and its use in the 125I-C1q binding assay for detection of immune complexes.
Wu CC; Bey RF; Loken KI
Am J Vet Res; 1988 Jun; 49(6):865-9. PubMed ID: 3135770
[TBL] [Abstract][Full Text] [Related]
26. Co-operative interaction of subcomponents of the first component of complement with IgG: a functional defect of dimeric Facb from rabbit IgG.
Okada M; Udaka K; Utsumi S
Mol Immunol; 1985 Dec; 22(12):1399-406. PubMed ID: 3007976
[TBL] [Abstract][Full Text] [Related]
27. Reconstitution of C1 in native proenzyme form and its use in a quantitative C1 activation test.
Cooper NR; Ziccardi RJ
J Immunol; 1977 Nov; 119(5):1664-7. PubMed ID: 915274
[TBL] [Abstract][Full Text] [Related]
28. Critical aspects of the 125I-C1q binding assay for detecting immune complexes in tumor patients.
Krieger G; Bause I; Kneba M; Kehl A; Nagel GA
J Clin Lab Immunol; 1984 Jun; 14(2):87-92. PubMed ID: 6611419
[TBL] [Abstract][Full Text] [Related]
29. Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism.
Ziccardi RJ
J Immunol; 1982 Jun; 128(6):2500-4. PubMed ID: 6281332
[TBL] [Abstract][Full Text] [Related]
30. Stoichiometry and sedimentation properties of the complex formed between the C1q and C1r2C1s2 subcomponents of the first component of complement.
Siegel RC; Schumaker VN; Poon PH
J Immunol; 1981 Dec; 127(6):2447-52. PubMed ID: 6975324
[TBL] [Abstract][Full Text] [Related]
31. Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats.
Johansson AG; Løvdal T; Magnusson KE; Berg T; Skogh T
Hepatology; 1996 Jul; 24(1):169-75. PubMed ID: 8707258
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the hemolytic activity of the first component of complement C1 by an Escherichia coli C1q binding protein.
van den Berg RH; Faber-Krol MC; van de Klundert JA; van Es LA; Daha MR
J Immunol; 1996 Jun; 156(11):4466-73. PubMed ID: 8666822
[TBL] [Abstract][Full Text] [Related]
33. Clearance kinetics and tissue distribution of aggregated human serum IgA in rats.
Bogers WM; Gorter A; Stuurman ME; Van Es LA; Daha MR
Immunology; 1989 Jun; 67(2):274-80. PubMed ID: 2473956
[TBL] [Abstract][Full Text] [Related]
34. Requirements for the binding of human plasma fibronectin to the C1q subunit of the first component of complement.
Sorvillo J; Gigli I; Pearlstein E
J Immunol; 1983 Sep; 131(3):1400-4. PubMed ID: 6309962
[TBL] [Abstract][Full Text] [Related]
35. Abnormal clearance of soluble aggregates of human immunoglobulin G in patients with systemic lupus erythematosus.
Lobatto S; Daha MR; Breedveld FC; Pauwels EK; Evers-Schouten JH; Voetman AA; Cats A; Van Es LA
Clin Exp Immunol; 1988 Apr; 72(1):55-9. PubMed ID: 3396221
[TBL] [Abstract][Full Text] [Related]
36. Influence of immune-complex size and antigen-antibody ratio on immune complex detection with monoclonal rheumatoid factor and C1q.
Vanham G; Bloemmen FJ; Ceuppens JL; Stevens EA
J Clin Lab Immunol; 1984 Oct; 15(2):63-8. PubMed ID: 6335179
[TBL] [Abstract][Full Text] [Related]
37. The binding site for C1q on IgG.
Duncan AR; Winter G
Nature; 1988 Apr; 332(6166):738-40. PubMed ID: 3258649
[TBL] [Abstract][Full Text] [Related]
38. In vivo fate of 125I SS-B (La) injected into mice.
Schrieber L; Erhardt CC; Melsom RD; Venables PJ; McCarthy DA; Mumford PA; Horsfall AC; Maini RN
Immunology; 1983 Apr; 48(4):771-8. PubMed ID: 6832805
[TBL] [Abstract][Full Text] [Related]
39. The use of TNP-conjugated polyacrylamide beads in a C1q binding inhibition test for circulating immune complexes.
Schmidt R; Walther S; Sodomann CP
Immunobiology; 1982; 162(2):153-64. PubMed ID: 6981581
[TBL] [Abstract][Full Text] [Related]
40. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.
Tas SW; Klickstein LB; Barbashov SF; Nicholson-Weller A
J Immunol; 1999 Nov; 163(9):5056-63. PubMed ID: 10528211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
